Anti-Human EGFR Recombinant Antibody (TAB-119)

Customer Review

There are currently no Customer reviews or questions for TAB-119. Click the button above to contact us or submit your feedback about this product.

Q&As

1. Is the anti-Human EGFR therapeutic antibody Necitumumab suitable for use in Western blotting?

   A: Yes, the anti-Human EGFR therapeutic antibody Necitumumab (TAB-119) is suitable for use in Western blotting. It provides specific binding to EGFR, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-Human EGFR therapeutic antibody Necitumumab?

   A: The recommended storage condition for the anti-Human EGFR therapeutic antibody Necitumumab (TAB-119) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human EGFR therapeutic antibody Necitumumab be used in immunoprecipitation assays?

   A: Yes, the anti-Human EGFR therapeutic antibody Necitumumab (TAB-119) can be used in immunoprecipitation assays. It provides specific binding to EGFR, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Human EGFR therapeutic antibody Necitumumab effective in ELISA applications?

   A: Yes, the anti-Human EGFR therapeutic antibody Necitumumab (TAB-119) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of EGFR.

5. What is the optimal dilution for using the anti-Human EGFR therapeutic antibody Necitumumab in immunofluorescence?

   A: The optimal dilution for using the anti-Human EGFR therapeutic antibody Necitumumab (TAB-119) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Lu, Xinmiao, et al. "Radiolabeling and biological evaluation of 125 I-Necitumumab for EGFR-targeted SPECT imaging." Journal of Radioanalytical and Nuclear Chemistry 323 (2020): 83-89. https://doi.org/10.1007/s10967-019-06933-8
   The study aimed to develop and evaluate a SPECT probe, 125I-Necitumumab, targeting the epidermal growth factor receptor (EGFR) for imaging non-small cell lung cancer (NSCLC). The researchers synthesized 125I-Necitumumab via the iodogen oxidation method and assessed its potential for SPECT imaging in vivo. The biodistribution study indicated rapid clearance of 125I-Necitumumab in most organs, with no significant uptake in tumor tissues despite the high EGFR expression. Consequently, the study concluded that 125I-Necitumumab is unsuitable for EGFR-targeted SPECT imaging of NSCLC.
   Creative Biolabs provided the anti-human EGFR recombinant antibody Necitumumab (Cat#: TAB-119). The involvement of Creative Biolabs was crucial for obtaining the high-affinity EGFR-targeted antibody, enabling the researchers to synthesize the 125I-Necitumumab probe. This contribution facilitated the comprehensive evaluation of the probe's practicality for SPECT imaging, despite the final determination of its unsuitability for EGFR-targeted imaging in NSCLC.
2. Rasoulouniriana, Diana, et al. "T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors." Cancer Immunology Research 11.6 (2023): 792-809. https://doi.org/10.1158/2326-6066.CIR-22-0423
   The study focused on engineering a modified FcgRI receptor for T cells, aiming to enhance their antibody-dependent cytotoxicity (ADCC) against solid tumors. This new receptor allows T cells to target tumor cells using antibodies, demonstrating effective and specific cytotoxicity only in the presence of appropriate antibodies. The engineered T cells, tested in both immunocompetent and immunodeficient mice, showed significant tumor eradication while secreting lower levels of cytokines compared to traditional CAR T cells, thus enhancing their safety profile. This technology offers a versatile approach, enabling the same engineered T cells to target different tumors by simply changing the injected antibody.
   Creative Biolabs contributed by providing several critical antibodies for the study. Specifically, Creative Biolabs supplied Sofituzumab (Cat#: TAB-H63) and Necitumumab (Cat#: TAB-119). These antibodies were essential for testing the ADCC capabilities of the modified T cells, as they facilitated the targeting of specific tumor antigens, demonstrating the versatility and efficacy of the engineered T cells in preclinical models.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-119, RRID: AB_3111823)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Peer-reviewed Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Lu, Xinmiao, et al. "Radiolabeling and biological evaluation of 125 I-Necitumumab for EGFR-targeted SPECT imaging." Journal of Radioanalytical and Nuclear Chemistry (2019): 1-7.

Biosimilar Overview

Please refer to Necitumumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Necitumumab.

Related Diseases

Related Signaling Pathways

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "EGFR"

Select a product category from the dropdown menu below to view related products.

Single Domain Antibodies Chimeric Antibodies Humanized Antibodies Mouse Antibodies Human Antibodies Fc Glycosylation Antibodies High-mannose Glycoform Antibodies Deglycosylated Antibodies Chicken IgY Antibodies MHC Tetramers for Cancer Neutralizing Antibodies Rabbit Monoclonal Antibodies Fab Antibodies IgG Antibodies ScFv Antibodies ADCC Enhanced Antibodies Antibody Magnetic Beads Cancer Stem Cell Biomarker Specific Antibodies NHP Antibodies ScFv-Fc Chimeras FC Reagents & Kits IHC Kits & Antibodies Extracellular Vesicle Antibodies Biparatopic Antibodies